

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1054202/m-a-odonnell-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138 papers	5,201 citations	41 h-index	67 g-index
147 ext. papers	5,950 ext. citations	4 avg, IF	5.46 L-index

#	Paper	IF	Citations
138	BCG immunotherapy of bladder cancer: 20 years on. <i>Lancet, The</i> , 1999 , 353, 1689-94	4.0	353
137	Management of stage T1 tumors of the bladder: International Consensus Panel. <i>Urology</i> , 2005 , 66, 108-256		326
136	Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. <i>Journal of Urology</i> , 2003 , 169, 946-50	2.5	269
135	Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 344-8	2.8	192
134	Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. <i>Cancer Research</i> , 2004 , 64, 3386-90	10.1	147
133	Intravesical treatments of bladder cancer: review. <i>Pharmaceutical Research</i> , 2008 , 25, 1500-10	4.5	128
132	The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. <i>European Urology</i> , 2010 , 57, 410-29	10.2	125
131	The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. <i>Journal of Urology</i> , 2006 , 175, 1634-9; discussion 1639-40	2.5	114
130	Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 225-35	5.5	101
129	Superficial bladder cancer: the role of interferon-alpha. <i>Journal of Urology</i> , 1998 , 159, 1793-801	2.5	101
128	Bacillus Calmette-Guérin with or without interferon α 2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2010 , 184, 1915-9	2.5	95
127	Bladder Cancer Immunotherapy: BCG and Beyond. <i>Advances in Urology</i> , 2012 , 2012, 181987	1.6	87
126	Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. <i>Cytokine</i> , 2003 , 21, 17-26	4	87
125	Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alfa-2b for superficial bladder cancer. <i>Journal of Urology</i> , 2004 , 172, 888-93	2.5	85
124	Role of neutrophils in BCG immunotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 341-5	2.8	81
123	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018 , 73, 738-748	10.2	77
122	Phase I trial of intravesical recombinant adenovirus mediated interferon- α 2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2013 , 190, 850-6	2.5	76

121	Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 35.e15-9	2.8	73
120	Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. <i>Urology</i> , 2008 , 71, 297-301	1.6	73
119	Treatment options for BCG failures. <i>World Journal of Urology</i> , 2006 , 24, 481-7	4	70
118	Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. <i>European Urology</i> , 2007 , 52, 1700-8	10.2	64
117	Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. <i>Bladder Cancer</i> , 2015 , 1, 29-30	1	59
116	Bacillus Calmette-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 354-60	2.8	59
115	Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. <i>Journal of Immunotherapy</i> , 2003 , 26, 343-8	5	58
114	Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. <i>Clinical and Experimental Immunology</i> , 2004 , 137, 24-34	6.2	57
113	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. <i>Journal of Urology</i> , 2018 , 199, 1158-1165	2.5	56
112	The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. <i>BJU International</i> , 2009 , 103, 475-9	5.6	56
111	Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. <i>Clinical and Experimental Immunology</i> , 2003 , 131, 206-16	6.2	54
110	Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. <i>Journal of Immunotherapy</i> , 2004 , 27, 116-23	5	54
109	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology, The</i> , 2021 , 22, 107-117	21.7	53
108	Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: Associations with painful symptoms. <i>Pain</i> , 2014 , 155, 1755-1761	8	51
107	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma 2017 , 5, 68		48
106	Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. <i>Urology</i> , 2014 , 83, 262-4	1.6	48
105	Bladder cancer: narrowing the gap between evidence and practice. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5680-4	2.2	47
104	Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2015 , 1, 65-72	1	43

103	The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder. <i>Cancer and Metastasis Reviews</i> , 2009 , 28, 345-53	9.6	43
102	Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1647-55	7.4	43
101	Toll-like receptor 4 and comorbid pain in Interstitial Cystitis/Bladder Pain Syndrome: a multidisciplinary approach to the study of chronic pelvic pain research network study. <i>Brain, Behavior, and Immunity</i> , 2015 , 49, 66-74	16.6	42
100	Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. <i>Clinical and Experimental Immunology</i> , 2007 , 147, 370-8	6.2	42
99	Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. <i>Journal of Urology</i> , 2004 , 171, 1330-5	2.5	41
98	Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. <i>Urology</i> , 2003 , 62, 1083-8	1.6	41
97	Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. <i>Clinical and Experimental Immunology</i> , 2001 , 123, 264-70	6.2	40
96	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 776-785	21.7	38
95	Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. <i>Journal of Urology</i> , 2011 , 186, 817-23	2.5	36
94	Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guérin secreting murine GM-CSF is associated with expansion and activation of APCs. <i>Journal of Immunology</i> , 2007 , 179, 8418-24	5.3	36
93	An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine-secreting BCG vaccines. <i>Immunology</i> , 1999 , 96, 517-23	7.8	36
92	Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2020 , 203, 902-909	2.5	36
91	Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. <i>Clinical and Developmental Immunology</i> , 2011 , 2011, 728930		35
90	Advances in the management of superficial bladder cancer. <i>Seminars in Oncology</i> , 2007 , 34, 85-97	5.5	33
89	The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. <i>European Urology</i> , 2004 , 46, 670-4	10.2	33
88	Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guérin. <i>Immunology and Cell Biology</i> , 2002 , 80, 209-15	5	33
87	Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 35.e21-30	2.8	31
86	Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper?. <i>Journal of Urology</i> , 2004 , 172, 1056-61	2.5	31

85	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. <i>Nature Reviews Urology</i> , 2019 , 16, 377-386	5.5	30
84	Animal Models of Urologic Chronic Pelvic Pain Syndromes: Findings From the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network. <i>Urology</i> , 2015 , 85, 1454-65	1.6	30
83	Treatment of postoperative ileus after bowel surgery with low-dose intravenous erythromycin. <i>Urology</i> , 2007 , 69, 611-5	1.6	30
82	Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. <i>International Journal of Cancer</i> , 2004 , 112, 653-60	7.5	30
81	Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette-Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. <i>Clinical and Experimental Immunology</i> , 2014 , 177, 261-8	6.2	29
80	Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?. <i>BJU International</i> , 2006 , 97, 48-50	5.6	29
79	Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures. <i>Current Opinion in Urology</i> , 2004 , 14, 271-5	2.8	28
78	Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2011 , 16, 13-26	5.4	26
77	Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. <i>Journal of Urology</i> , 2001 , 166, 1300-4, discussion 1304-5	2.5	26
76	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 51-60	4	25
75	Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study. <i>PLoS ONE</i> , 2016 , 11, e0168772	3.7	24
74	Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. <i>Journal of Urology</i> , 2012 , 187, 2228-35	2.5	23
73	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202 ¹		22
72	Recognition and treatment of BCG failure in bladder cancer. <i>Scientific World Journal, The</i> , 2011 , 11, 602-132		22
71	Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha. <i>BMC Immunology</i> , 2008 , 9, 4	3.7	22
70	Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. <i>Urologic Clinics of North America</i> , 2005 , 32, 121-31	2.9	22
69	Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. <i>Cancer Immunology, Immunotherapy</i> , 1996 , 42, 280-4	7.4	22
68	Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer. <i>Current Urology Reports</i> , 2016 , 17, 38	2.9	22

67	Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles. <i>Cancer Nanotechnology</i> , 2016 , 7, 3	7.9	22
66	The genetic reconstruction of BCG as a new immunotherapeutic tool. <i>Trends in Biotechnology</i> , 1997 , 15, 512-7	15.1	21
65	840: Intravesical Sequential Gemcitabine-Mitomycin Chemotherapy as Salvage Treatment for Patients with Refractory Superficial Bladder Cancer. <i>Journal of Urology</i> , 2006 , 175, 271-271	2.5	21
64	Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment. <i>Computers in Biology and Medicine</i> , 2006 , 36, 634-55	7	20
63	Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. <i>Bladder Cancer</i> , 2016 , 2, 215-224	1	20
62	Peptide-Mediated Targeting Mesoporous Silica Nanoparticles: A Novel Tool for Fighting Bladder Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2017 , 13, 232-42	4	19
61	Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: impact on patient outcomes and costs. <i>Urology</i> , 2005 , 65, 488-92	1.6	19
60	Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts. <i>Journal of Urology</i> , 2015 , 194, 230-7	2.5	18
59	Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon- β . <i>Journal of Urology</i> , 2011 , 185, 67-71	2.5	18
58	Combination of BCG and interferon intravesical immunotherapy: an update. <i>World Journal of Urology</i> , 2009 , 27, 343-6	4	18
57	The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder. <i>Journal of Urology</i> , 2004 , 171, 1336-42	2.5	17
56	Inflammation and Symptom Change in Interstitial Cystitis or Bladder Pain Syndrome: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study. <i>Urology</i> , 2016 , 90, 56-61	1.6	16
55	Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B. <i>Journal of Urology</i> , 1997 , 158, 2311-5	2.5	16
54	Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 809-21	3.5	15
53	Interleukin-12. Opportunities for the treatment of bladder cancer. <i>Urologic Clinics of North America</i> , 2000 , 27, 147-55	2.9	15
52	Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020 , 3, 318-340	6.7	14
51	Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 670.e7-670.e14	2.8	14
50	Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins. <i>BMC Cancer</i> , 2007 , 7, 204	4.8	14

49	Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy. <i>BMC Urology</i> , 2015 , 15, 45	2.2	13
48	Treatment options in non-muscle-invasive bladder cancer after BCG failure. <i>Indian Journal of Urology</i> , 2015 , 31, 312-9	0.8	13
47	Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 201-207	2.8	12
46	Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018 , 4, 503-505	5.1	12
45	Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study. <i>Scientific Reports</i> , 2018 , 8, 6573	4.9	12
44	Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. <i>BJU International</i> , 2019 , 123, 35-41	5.6	12
43	Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease. <i>Bladder Cancer</i> , 2015 , 1, 105-116	1	12
42	Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells. <i>Clinical and Experimental Immunology</i> , 2007 , 149, 178-85	6.2	12
41	Patient resources available to bladder cancer patients: a pilot study of healthcare providers. <i>Urology</i> , 2012 , 79, 172-7	1.6	11
40	Optimizing BCG therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 325-8	2.8	11
39	Transgenic Mice Expressing MCP-1 by the Urothelium Demonstrate Bladder Hypersensitivity, Pelvic Pain and Voiding Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study. <i>PLoS ONE</i> , 2016 , 11, e0163829	3.7	11
38	Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model. <i>Journal of Urology</i> , 2004 , 172, 2414-20	2.5	10
37	Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer. <i>International Journal of Urology</i> , 2012 , 19, 988-93	2.3	9
36	Risk-adapted use of intravesical immunotherapy. <i>BJU International</i> , 2008 , 102, 1254-64	5.6	9
35	Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: a MAPP Research Network animal study. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 317, F90-F98	4.3	8
34	A novel expression of macrophage derived chemokine in human bladder cancer. <i>Journal of Urology</i> , 2005 , 173, 990-5	2.5	8
33	Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018 , 4, 512-521	5.1	8
32	Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α 2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices. <i>Journal of Urology</i> , 2010 , 184, 1920-4	2.5	7

31	Does the probiotic <i>L. casei</i> help prevent recurrence after transurethral resection for superficial bladder cancer?. <i>Nature Reviews Urology</i> , 2008 , 5, 526-7		7
30	Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?. <i>Nature Reviews Urology</i> , 2007 , 4, 304-5		7
29	Review of topical treatment of upper tract urothelial carcinoma. <i>Advances in Urology</i> , 2009 , 472831	1.6	6
28	MUTATEDRASp21 AS A TARGET FOR CANCER THERAPY IN MOUSE TRANSITIONAL CELL CARCINOMA. <i>Journal of Urology</i> , 1999 , 162, 1519-1526	2.5	6
27	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. <i>Bladder Cancer</i> , 2017 , 3, 145-146	1	5
26	Minimally invasive management of upper tract urothelial carcinoma. <i>Current Urology Reports</i> , 2006 , 7, 23-30	2.9	5
25	Severe Infectious Complications of Intravesical Bacillus Calmette-Guérin: A Case Series of 10 Patients. <i>Urology</i> , 2020 , 137, 79-83	1.6	5
24	Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival. <i>Prostate International</i> , 2016 , 4, 107-12	3.4	5
23	Rubin H. Flocks and colloidal gold treatments for prostate cancer. <i>Scientific World Journal, The</i> , 2011 , 11, 1560-7	2.2	4
22	Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin. <i>Journal of Urology</i> , 2006 , 175, 1197-8	2.5	4
21	Autoimmunity to urothelial antigen causes bladder inflammation, pelvic pain, and voiding dysfunction: a novel animal model for Hunner-type interstitial cystitis. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, F174-F182	4.3	4
20	Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. Tinacci, E. Zini, N. Mondaini, v. Boddi, s. Mazzoli and P. Bortolan. <i>Urology</i> , 2020 , 168, 148-149. <i>Journal of Urology</i> , 2020 , 181, 148	2.5	3
19	Overexpression of HIF1 α in Hunner Lesions of Interstitial Cystitis: Pathophysiological Implications. <i>Journal of Urology</i> , 2021 , 101097JU00000000000002278	2.5	3
18	Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach. <i>BMC Health Services Research</i> , 2020 , 20, 686	2.9	3
17	Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 , 40, 9.e1-9.e7	2.8	3
16	Intravesical Therapy [BCG and Beyond. <i>Bladder Cancer</i> , 2019 , 5, 73-80	1	2
15	Reply by the authors. <i>Urology</i> , 2014 , 84, 495-6	1.6	2
14	New imaging techniques for non-muscle invasive bladder cancer: ready for primetime. <i>Urologic Clinics of North America</i> , 2013 , 40, 271-9	2.9	1

13	Intravesical colonic pseudotumor. <i>Journal of Urology</i> , 2004 , 171, 340	2.5	1
12	Reply by Authors.. <i>Journal of Urology</i> , 2022 , 101097JU0000000000000235002	2.5	1
11	Combination Intravesical Therapy. <i>Urologic Clinics of North America</i> , 2020 , 47, 83-91	2.9	1
10	Non-Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018 , 6, 2324709618806332	1.2	1
9	Phase Ib study of avelumab and taxane based chemotherapy in platinum-refractory or ineligible metastatic urothelial cancer (AVETAX study).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 503-503	2.2	1
8	Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. <i>Journal of Cutaneous Pathology</i> , 2018 , 45, 453-457	1.7	0
7	VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 488-488	2.2	0
6	Transitional cell carcinoma--tantalizing issues of tumor biology. <i>Journal of Urology</i> , 1996 , 156, 961	2.5	
5	Reply by Authors.. <i>Journal of Urology</i> , 2022 , 207, 646	2.5	
4	Intravesical immunotherapy76-88		
3	Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 497-497	2.2	
2	Sequential intravesical valrubicin and docetaxel for the treatment of nonmuscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 496-496	2.2	
1	Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 573-573	2.2	